Compounds > nevirapine

nevirapine and zalcitabine

nevirapine has been researched along with zalcitabine in 42 studies

Research

Studies (42)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's17 (40.48)18.2507
2000's7 (16.67)29.6817
2010's17 (40.48)24.3611
2020's1 (2.38)2.80

Authors

AuthorsStudies
Topliss, JG; Yoshida, F1
Singh, SK; Yadav, A1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Lombardo, F; Obach, RS; Waters, NJ1
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Balzarini, J; Chen, FE; De Clercq, E; Gu, SX; He, QQ; Ma, XD; Pannecouque, C; Yang, SQ1
Chen, W; Chen, X; De Clercq, E; Li, D; Li, X; Liu, X; Pannecouque, C; Tian, Y; Zhan, P1
Balzarini, J; Chen, X; De Clercq, E; Liu, X; Pannecouque, C; Zhan, P1
Chen, X; Cheng, Z; De Clercq, E; Liu, X; Meng, C; Pannecouque, C; Shao, S; Zhan, P1
Balzarini, J; Chen, X; De Clercq, E; Li, D; Li, X; Liu, H; Liu, X; Pannecouque, C; Wang, L; Zhan, P1
Chen, W; Chen, X; De Clercq, E; Li, X; Li, Z; Liu, X; Pannecouque, C; Tian, Y; Zhan, P1
Chen, W; Chen, X; Clercq, ED; Li, X; Li, Z; Liu, X; Pannecouque, C; Tian, Y; Zhan, P1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Balzarini, J; Chen, FE; Chen, WX; Daelemans, D; De Clercq, E; He, QQ; Pannecouque, C; Wu, HQ; Yan, ZH1
Balzarini, J; Chen, W; De Clercq, E; Jiang, X; Liu, X; Pannecouque, C; Zhan, P1
Balzarini, J; Chen, W; De Clercq, E; Liu, H; Liu, X; Pannecouque, C; Rai, D; Zhan, P; Zhou, Z1
Bingöl Özakpınar, Ö; De Clercq, E; Küçükgüzel, İ; Kulabaş, N; Özsavcı, D; Pannecouque, C; Tatar, E1
Buckheit, RW; Cushman, M; Hartman, TL; Hoshi, A; Okazaki, M; Pannecouque, C; Sakamoto, T; Takayama, J; Xuan, M1
Jones, LH; Nadanaciva, S; Rana, P; Will, Y1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M1
Connell, EV; Hsu, MC; Richman, DD1
López-Galíndez, C; Nájera, I; Nájera, R; Olivares, I; Peinado, MA; Perucho, M; Richman, DD; Rojas, JM1
Brennan, TM; Bridges, CG; Leyda, JP; Taylor, DL; Tyms, AS1
Barry, DW; Pennington, KN; Rooney, J; St Clair, MH1
Richman, DD1
Baba, M; Hashimoto, KI; Okamoto, M; Shigeta, S; Tsunoda, R1
Hirschel, B; Rutschmann, O1
Collins, DO; Sakamoto, A1
Saag, MS; Schooley, RT1
Balfour, HH; Erice, A; Fischl, MA; Henry, K; Hirsch, MS; Kahn, JO; Kenton, A; Kmack, A; Liou, SH; Martinez, A; Phair, J; Tierney, C1
Temesgen, Z; Wright, AJ1
Allende, MC; Belloso, WH; Benetucci, JA; Cahn, PE; Davey, RT; Emery, S; Lane, HC; Lasala, MC; Law, MG; Lopardo, G; Losso, MH; Nelson, E; Salomon, H; Saracco, M1
Gilden, D1
James, JS1
Doepel, L; Folkers, G1
MacDougall, DS1
Baker, SG; Fitzmaurice, GM; Freedman, LS; Kramer, BS1

Reviews

4 review(s) available for nevirapine and zalcitabine

ArticleYear
Resistance, drug failure, and disease progression.
    AIDS research and human retroviruses, 1994, Volume: 10, Issue:8

    Topics: Antiviral Agents; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Humans; Nevirapine; Pyridines; Randomized Controlled Trials as Topic; Zalcitabine; Zidovudine

1994
Antiretroviral therapy: a guide to the most important trials.
    Schweizerische medizinische Wochenschrift, 1997, Mar-15, Volume: 127, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nevirapine; Pyridines; Ritonavir; Saquinavir; Stavudine; Viral Load; Zalcitabine; Zidovudine

1997
Antiretroviral chemotherapy.
    Current clinical topics in infectious diseases, 1998, Volume: 18

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine

1998
Antiretrovirals.
    Mayo Clinic proceedings, 1999, Volume: 74, Issue:12

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine

1999

Trials

4 trial(s) available for nevirapine and zalcitabine

ArticleYear
Resistance, drug failure, and disease progression.
    AIDS research and human retroviruses, 1994, Volume: 10, Issue:8

    Topics: Antiviral Agents; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Humans; Nevirapine; Pyridines; Randomized Controlled Trials as Topic; Zalcitabine; Zidovudine

1994
A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study T
    Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, 1998, Dec-01, Volume: 19, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV; Humans; Male; Nevirapine; Placebos; Reverse Transcriptase Inhibitors; RNA, Viral; Survival Rate; Time Factors; Zalcitabine; Zidovudine

1998
A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
    The Journal of infectious diseases, 2000, Volume: 181, Issue:5

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Didanosine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Indinavir; Injections, Subcutaneous; Interleukin-2; Lamivudine; Lymphocyte Count; Male; Nelfinavir; Nevirapine; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Zalcitabine; Zidovudine

2000
New double vs. triple antiviral combination study, CD4 200-500, no prior treatment.
    AIDS treatment news, 1995, Dec-01, Issue:no 236

    Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Nevirapine; Pyridines; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine

1995

Other Studies

35 other study(ies) available for nevirapine and zalcitabine

ArticleYear
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
Threshold interaction energy of NRTI's (2'-deoxy 3'-substituted nucleosidic analogs of reverse transcriptase inhibitors) to undergo competitive inhibition.
    Bioorganic & medicinal chemistry letters, 2004, May-17, Volume: 14, Issue:10

    Topics: Anti-HIV Agents; Binding, Competitive; Inhibitory Concentration 50; Models, Molecular; Nucleosides; Protein Binding; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Thermodynamics

2004
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
    Bioorganic & medicinal chemistry, 2009, Jan-15, Volume: 17, Issue:2

    Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.
    Bioorganic & medicinal chemistry, 2011, Sep-01, Volume: 19, Issue:17

    Topics: Aniline Compounds; Cell Line; Chlorine; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2011
Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:10

    Topics: Acetamides; Anti-HIV Agents; Cell Line; HIV Infections; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Triazoles; Virus Replication

2011
Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
    European journal of medicinal chemistry, 2012, Volume: 51

    Topics: Anti-HIV Agents; Cell Line; Chemistry Techniques, Synthetic; HIV Reverse Transcriptase; HIV-1; Inhibitory Concentration 50; Piperidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Triazines

2012
Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.
    Bioorganic & medicinal chemistry, 2012, Jun-15, Volume: 20, Issue:12

    Topics: Amines; Anti-HIV Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Piperidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Triazines

2012
Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors.
    Bioorganic & medicinal chemistry, 2012, Sep-15, Volume: 20, Issue:18

    Topics: Acetanilides; Anti-HIV Agents; Cell Line; Dose-Response Relationship, Drug; Drug Design; HIV-1; Humans; Imidazoles; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship; Virus Replication

2012
Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.
    Bioorganic & medicinal chemistry letters, 2012, Dec-01, Volume: 22, Issue:23

    Topics: Binding Sites; Cell Line; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Protein Structure, Tertiary; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Thioglycolates; Triazines

2012
Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.
    Bioorganic & medicinal chemistry, 2012, Dec-01, Volume: 20, Issue:23

    Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Structure-Activity Relationship; Thioacetamide

2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
    Bioorganic & medicinal chemistry, 2013, Nov-01, Volume: 21, Issue:21

    Topics: Binding Sites; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Protein Binding; Protein Structure, Tertiary; Pyrimidines; Pyrimidinones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2013
Design, synthesis and biological evaluation of N2,N4-disubstituted-1,1,3-trioxo-2H,4H-pyrrolo[1,2-b][1,2,4,6]thiatriazine derivatives as HIV-1 NNRTIs.
    Bioorganic & medicinal chemistry, 2013, Nov-15, Volume: 21, Issue:22

    Topics: Binding Sites; Cell Line; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Protein Structure, Tertiary; Pyrroles; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Triazines

2013
Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays.
    Bioorganic & medicinal chemistry, 2014, Mar-15, Volume: 22, Issue:6

    Topics: Anti-HIV Agents; Crystallization; Dose-Response Relationship, Drug; Drug Discovery; HIV Reverse Transcriptase; HIV-1; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Pyridones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2014
Synthesis and antiproliferative evaluation of novel 2-(4H-1,2,4-triazole-3-ylthio)acetamide derivatives as inducers of apoptosis in cancer cells.
    European journal of medicinal chemistry, 2016, Oct-04, Volume: 121

    Topics: Acetamides; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Humans; Membrane Potential, Mitochondrial; Structure-Activity Relationship; Triazoles

2016
Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
    Bioorganic & medicinal chemistry, 2016, 07-01, Volume: 24, Issue:13

    Topics: Anti-HIV Agents; Drug Stability; Esters; HIV-1; Humans; Inhibitory Concentration 50; Methane; Models, Molecular; Reverse Transcriptase Inhibitors

2016
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
    Bioorganic & medicinal chemistry letters, 2016, 08-15, Volume: 26, Issue:16

    Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone

2016
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

    Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023
Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor.
    Antimicrobial agents and chemotherapy, 1994, Volume: 38, Issue:2

    Topics: Antiviral Agents; Benzodiazepines; Didanosine; Drug Synergism; Gene Products, tat; HeLa Cells; HIV; HIV Protease Inhibitors; Humans; Isoquinolines; Nevirapine; Pyridines; Pyrroles; Quinolines; Reverse Transcriptase Inhibitors; Saquinavir; tat Gene Products, Human Immunodeficiency Virus; Zalcitabine; Zidovudine

1994
Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates.
    AIDS research and human retroviruses, 1994, Volume: 10, Issue:11

    Topics: Amino Acid Sequence; Antiviral Agents; Base Sequence; Cloning, Molecular; DNA, Viral; Drug Resistance, Microbial; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Mutation; Nevirapine; Point Mutation; Polymerase Chain Reaction; Pyridines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Stavudine; Virus Cultivation; Zalcitabine; Zidovudine

1994
The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds.
    Antiviral research, 1995, Volume: 26, Issue:2

    Topics: Antiviral Agents; Cells, Cultured; Cytotoxicity Tests, Immunologic; Didanosine; Drug Interactions; HIV Reverse Transcriptase; HIV-1; Humans; Indolizines; Isoquinolines; Leukocytes, Mononuclear; Molecular Structure; Nevirapine; Pyridines; Quinolines; Reverse Transcriptase Inhibitors; Saquinavir; Uracil; Zalcitabine; Zidovudine

1995
In vitro comparison of selected triple-drug combinations for suppression of HIV-1 replication: the Inter-Company Collaboration Protocol.
    Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, 1995, Volume: 10 Suppl 2

    Topics: Antiviral Agents; Cell Line, Transformed; Cytopathogenic Effect, Viral; Didanosine; Drug Synergism; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Lamivudine; Nevirapine; Pyridines; Quinolines; Reverse Transcriptase Inhibitors; Saquinavir; Virus Replication; Zalcitabine; Zidovudine

1995
Stavudine selectively induces apoptosis in HIV type 1-infected cells.
    AIDS research and human retroviruses, 1997, Jan-20, Volume: 13, Issue:2

    Topics: Anti-HIV Agents; Apoptosis; Cell Line; Didanosine; DNA Fragmentation; Down-Regulation; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Proto-Oncogene Proteins c-bcl-2; Pyridines; Reverse Transcriptase Inhibitors; Stavudine; T-Lymphocytes; Thymidine; Zalcitabine; Zidovudine

1997
Cure or control of HIV/AIDS?
    Medical hypotheses, 1997, Volume: 48, Issue:6

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Humans; Indinavir; Lamivudine; Models, Biological; Nevirapine; Pyridines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine

1997
Drugs for HIV infection.
    The Medical letter on drugs and therapeutics, 1997, Dec-12, Volume: 39, Issue:1015

    Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Delavirdine; Diarrhea; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Virus Replication; Zalcitabine; Zidovudine

1997
Changing cost of English HIV service provision 1996-1997. NPMS Steering Group. National Prospective Monitoring System.
    International journal of STD & AIDS, 1999, Volume: 10, Issue:6

    Topics: Adult; Anti-HIV Agents; Didanosine; Drug Costs; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Hospital Costs; Humans; Nevirapine; RNA-Directed DNA Polymerase; United Kingdom; Zalcitabine; Zidovudine

1999
New combo trial/same old style.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1995, Volume: 9, Issue:4

    Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Protocols; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Pyridines; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine

1995
NIAID researchers present new findings at retrovirus meeting. National Institute of Allergy and Infectious Diseases.
    NIAID AIDS agenda, 1997

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Chemokines; Clinical Trials as Topic; Clone Cells; Dendritic Cells; Didanosine; Disease Progression; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Interleukin-10; Killer Cells, Natural; Lamivudine; Male; Nevirapine; Pyridines; Receptors, Cytokine; Reverse Transcriptase Inhibitors; Ritonavir; Virus Replication; Zalcitabine; Zidovudine

1997
Update on nevirapine: quest for a niche.
    Journal of the International Association of Physicians in AIDS Care, 1997, Volume: 3, Issue:9

    Topics: Adult; Anti-HIV Agents; Child; Clinical Trials as Topic; Didanosine; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Infant, Newborn; Nevirapine; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine

1997
Simple adjustments for randomized trials with nonrandomly missing or censored outcomes arising from informative covariates.
    Biostatistics (Oxford, England), 2006, Volume: 7, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Humans; Likelihood Functions; Longitudinal Studies; Models, Statistical; Nevirapine; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Zalcitabine; Zidovudine

2006